US5320824A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radionuclide labelled particles useful for radiation synovectomy
Assignee: Mallinckrodt Inc
•
Filing: 1993-04-16
•
Granted: 1994-06-14
•
Expires: 2013-04-16
Abstract
Abstract The present invention provides radiation synovectomy compositions for treating inflamed synovium containing a radionuclide complex bound to a substantially insoluble particle as the radiolabelled synovectomy agent in a sufficient amount of provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, the radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, the radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint it will be excreted from the body, the agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.
Inventors
- 👤 James W. Brodack
- 👤 Edward A. Deutsch
- 👤 Karen F. Deutsch
- 👤 Dennis L. Nosco
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:40
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1241; A61K51/1255; A61K2121/00
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
110 words
A radiation synovectomy composition for treating inflamed synovium containing a radionuclide complex bound to a substantially insoluble particle as the radiolabelled synovectomy agent in a sufficient amount to provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, said radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, said radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint it will be excreted from the body, said agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.
Claim 2
Dependent Claim
110 words
A radiation synovectomy composition for treating inflamed synovium containing a radionuclide complex bound to a substantially insoluble particle as the radiolabelled synovectomy agent in a sufficient amount to provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, said radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, said radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint it will be excreted from the body, said agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.
Claim 3
Dependent Claim
26 words
A composition according to claim 1, wherein said particle is selected from the group consisting of the albumin microspheres, sulfur colloid, glass beads, albumin, latex, hydroxyapatite.
Claim 4
Dependent Claim
29 words
A composition according to claim 2, wherein said complex is selected from the group consisting of a 188-Re complex, a 186-Re complex, a 153-Sm complex and a 156-Sm complex.
Claim 5
Dependent Claim
43 words
A composition according to claim 3, wherein said complex is selected from the group consisting of 188-Re MAG 3 complex, 186-Re MAG 3 complex, 188-Re DADS complex, 186-Re DADS complex, 188-Re HEDP complex, 186-Re HEDP complex, 153-Sm HEDP complex and 156-Sm HEDP complex.
Claim 6
Dependent Claim
26 words
A composition according to claim 2, wherein said particle is selected from the group consisting of the albumin microspheres, sulfur colloid, glass beads, albumin and latex.
Claim 7
Dependent Claim
23 words
A composition according to claim 5, wherein said complex is selected from the group consisting of a 188-Re complex and a 186-Re complex.
Claim 8
Dependent Claim
31 words
A composition according to claim 6, wherein said complex is selected from the group consisting of 188-Re MAG 3 complex, 186-Re MAG 3 complex, 188-Re DADS complex and 186-Re DADS complex.
Claim 9
Dependent Claim
34 words
A composition according to claim 5, wherein said particle is albumin and said complex is 188-Re MAG 3 complex or 186-Re MAG 3 complex, bound covalently to the albumin through the pendant carboxylate group.
Claim 10
Dependent Claim
17 words
A composition according to claim 2, wherein said particle is selected from the group consisting of hydroxyapatite.
Claim 11
Dependent Claim
29 words
A composition according to claim 9, wherein said complex is selected from the group consisting of a 188-Re complex, a 186-Re complex, a 153-Sm complex and a 156-Sm complex.
Claim 12
Dependent Claim
29 words
A composition according to claim 10, wherein said complex is selected from the group consisting of 188-Re HEDP complex, 186-Re HEDP complex, 153-Sm HEDP complex and 156-Sm HEDP complex.
Claim 13
Dependent Claim
29 words
A composition according to claim 10, wherein said complex is 186-Re HEDP, 188-Re HEDP, 153-Sm HEDP or 156-Sm HEDP bound covalently to the hydroxyapatite through the pendant calcium group.
Claim 14
Dependent Claim
21 words
A composition according to claim 9, wherein said particle of hydroxyapatite has a particle size of about 0.5 to 40 microns.
Claim 15
Independent Claim
153 words
A method for radiation synovectomy of the inflamed synovium wherein a radiation synovectomy composition containing a radiation synovectomy agent in a pharmaceutically acceptable radiation synovectomy vehicle is administered to the inflamed synovium in a sufficient amount to provide radiation synovectomy, the improvement comprising utilizing as the radiation synovectomy composition a composition containing a radionuclide complex bound to a substantially insoluble particle as the radiolabelled synovectomy agent in a sufficient amount to provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, said radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, said radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint, it will be excreted from the body said agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.
Claim 16
Independent Claim
153 words
A method for radiation synovectomy of the inflamed synovium wherein a radiation synovectomy composition containing a radiation synovectomy agent in a pharmaceutically acceptable radiation synovectomy vehicle is administered to the inflamed synovium in a sufficient amount to provide radiation synovectomy, the improvement comprising utilizing as the radiation synovectomy composition a composition containing a radionuclide complex bound to a substantially insoluble particle as the radiolabelled synovectomy agent in a sufficient amount to provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, said radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, said radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint, it will be excreted from the body said agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.
Claim 17
Dependent Claim
25 words
A method according to claim 14, wherein said particle is selected from the group consisting of albumin microspheres, sulfur colloid, glass beads, albumin, latex, hydroxyapatite.
Claim 18
Dependent Claim
29 words
A method according to claim 15, wherein said complex is selected from the group consisting of a 188-Re complex, a 186-Re complex, a 153-Sm complex, and a 156-Sm complex.
Claim 19
Dependent Claim
43 words
A method according to claim 16, wherein said complex is selected from the group consisting of 188-Re MAG 3 complex, 186-Re MAG 3 complex, 188-Re DADS complex, 186-Re DADS complex, 188-Re HEDP complex, 186-Re HEDP complex, 153-Sm HEDP complex and 156-Sm HEDP complex.
Claim 20
Dependent Claim
25 words
A method according to claim 15, wherein said particle is selected from the group consisting of albumin microspheres, sulfur colloid, glass beads, albumin and latex.
Claim 21
Dependent Claim
22 words
A method according to claim 18, wherein said complex is selected from the group consisting of a 188-Re and a 186-Re complex.
Claim 22
Dependent Claim
31 words
A method according to claim 19, wherein said complex is selected from the group consisting of 188-Re MAG 3 complex, 186-Re MAG 3 complex, 188-Re DADS complex and 186-Re DADS complex.
Claim 23
Dependent Claim
34 words
A method according to claim 19, wherein said particle is albumin and said complex is 188-Re MAG 3 complex or 186-Re MAG 3 complex bound covalently to the albumin through the pendant carboxylate group.
Claim 24
Dependent Claim
11 words
A method according to claim 15, wherein said particle is hydroxyapatite.
Claim 25
Dependent Claim
29 words
A method according to claim 22, wherein said complex is selected from the group consisting of a 188-Re complex, a 186-Re complex, a 153-Sm complex and a 156-Sm complex.
Claim 26
Dependent Claim
29 words
A method according to claim 23, wherein said complex is selected from the group consisting of 188-Re HEDP complex, 186-Re HEDP complex, 153-Sm HEDP complex and 156-Sm HEDP complex.
Claim 27
Dependent Claim
29 words
A method according to claim 23, wherein said complex is 188-Re HEDP, 186-Re HEDP, 153-Sm HEDP or 156-Sm HEDP bound covalently to the hydroxyapatite through the pendant calcium group.
Claim 28
Dependent Claim
23 words
A method according to claim 23, wherein said complex is 188-Re HEDP, 186-Re HEDP, 153-Sm HEDP or 156-Sm HEDP bound to the hydroxyapatite.
Claim 29
Dependent Claim
21 words
A method according to claim 22, wherein said particle of hydroxyapatite has a particle size of about 0.5 to 40 microns.
References Cited (Backward Citations)
USRE29066E
Cited
US3683066A
Cited
US4226846A
Cited
US4789501A
Cited
US4752464A
Cited
US4880007A
Cited
US4889707A
Cited
US5021235A
Cited
US5133956A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-06-13 | 1997-12-13 | 1998-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-06-13 | 2001-12-13 | 2002-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-06-13 | 2005-12-13 | 2006-06-14 | $7700.00 | Window Closed / Lapsed |